Cargando…

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort

PURPOSE: We aim to describe the treatment patterns and overall survival (OS) outcomes in patients receiving trastuzumab emtansine (T-DM1) for HER2-positive metastatic breast cancer (HER2+MBC) in routine clinical care. METHODS: Retrospective, whole-of-population cohort study of people initiating T-DM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daniels, Benjamin, Kiely, Belinda E., Tang, Monica, Houssami, Nehmat, Lord, Sarah J., Pearson, Sallie-Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138859/ https://www.ncbi.nlm.nih.gov/pubmed/33992964 http://dx.doi.org/10.1016/j.breast.2021.05.001

Ejemplares similares

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)
por: Daniels, Benjamin, et al.
Publicado: (2019)

Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort
por: Daniels, Benjamin, et al.
Publicado: (2017)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)
por: Tang, Monica, et al.
Publicado: (2019)

Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)
por: Tang, Monica, et al.
Publicado: (2020)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

Metastatic breast cancer incidence, site and survival in Australia, 2001–2016: a population-based health record linkage study protocol
por: Lord, Sarah J, et al.
Publicado: (2019)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022)

Long term risk of distant metastasis in women with non‐metastatic breast cancer and survival after metastasis detection: a population‐based linked health records study
por: Lord, Sarah (Sally) J, et al.
Publicado: (2022)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
por: Recondo, Gonzalo, et al.
Publicado: (2016)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report
por: Hassanieh, Ihab, et al.
Publicado: (2018)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Spring, Laura M., et al.
Publicado: (2021)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
por: Moghaddas, Azadeh, et al.
Publicado: (2016)

Opportunities for post-market surveillance of high cost medicines in Australia: Observing trastuzumab-treated women from early through late stage HER2-positive breast cancer (HER2BC)
por: Daniels, Benjamin, et al.
Publicado: (2017)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
por: Levicki, Rea, et al.
Publicado: (2023)

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
por: Cortés, Javier, et al.
Publicado: (2020)

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020)

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
por: Vici, Patrizia, et al.
Publicado: (2017)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
por: Corrêa, Tatiana Strava, et al.
Publicado: (2018)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
por: Krop, Ian E., et al.
Publicado: (2016)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
por: Wang, Lei, et al.
Publicado: (2018)

The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
por: Liu, Peipei, et al.
Publicado: (2020)

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
por: Magalhães, Marcos Aurélio Fonseca, et al.
Publicado: (2022)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus
por: Taha, Zaid, et al.
Publicado: (2023)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
por: Girish, Sandhya, et al.
Publicado: (2012)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nd1b59bg4sks1t8oceo8odktcp